Search
Related
Phase 1 dose-escalation trial evaluating the combination of the selective MET (mesenchymal-epithelial transition factor) inhibitor tivantinib (ARQ 197) plus erlotinib.
Goldman JW, Laux I, Chai F, Savage RE, Ferrari D, Garmey EG, Just RG, Rosen LS.
Cancer. 2012 May 17. doi: 10.1002/cncr.27575. [Epub ahead of print
22605616
[PubMed - as supplied by publisher] nohighlight
Related citations
Differential Sensitivity of Glioma- versus Lung Cancer-Specific EGFR Mutations to EGFR Kinase Inhibitors.
Vivanco I, Robins HI, Rohle D, Campos C, Grommes C, Nghiemphu PL, Kubek S, Oldrini B, Chheda MG, Yannuzzi N, Tao H, Zhu S, Iwanami A, Kuga D, Dang J, Pedraza A, Brennan CW, Heguy A, Liau LM, Lieberman F, Yung WK, Gilbert MR, Reardon DA, Drappatz J, Wen PY, Lamborn KR, Chang SM, Prados MD, Fine HA, Horvath S, Wu N, Lassman AB, Deangelis LM, Yong WH, Kuhn JG, Mischel PS, Mehta MP, Cloughesy TF, Mellinghoff IK.
Cancer Discov. 2012 May;2(5):458-471. Epub 2012 Mar 31
22588883
[PubMed - as supplied by publisher] nohighlight
Related citations
Amplification of CRKL Induces Transformation and Epidermal Growth Factor Receptor Inhibitor Resistance in Human Non-Small Cell Lung Cancers.
Cheung HW, Du J, Boehm JS, He F, Weir BA, Wang X, Butaney M, Sequist LV, Luo B, Engelman JA, Root DE, Meyerson M, Golub TR, Jänne PA, Hahn WC.
Cancer Discov. 2011 Dec;1(7):608-25. Epub 2011 Oct 17
22586683
[PubMed - in process] nohighlight
Related citations
Cytokines induce tight junction disassembly in airway cells via an EGFR-dependent MAPK/ERK1/2-pathway.
Petecchia L, Sabatini F, Usai C, Caci E, Varesio L, Rossi GA.
Lab Invest. 2012 May 14. doi: 10.1038/labinvest.2012.67. [Epub ahead of print
22584669
[PubMed - as supplied by publisher] nohighlight
Related citations
Quantitative immunohistochemistry for evaluating the distribution of ki67 and other biomarkers in tumor sections and use of the method to study repopulation in xenografts after treatment with Paclitaxel.
Fung AS, Jonkman J, Tannock IF.
Neoplasia. 2012 Apr;14(4):324-34
22577347
[PubMed - in process] Free PMC Article nohighlight
Related citations
Selected Reaction Monitoring (SRM) Analysis of Epidermal Growth Factor Receptor (EGFR) in Formalin Fixed Tumor Tissue.
Hembrough T, Thyparambil S, Liao WL, Darfler MM, Abdo J, Bengali KM, Taylor P, Tong J, Lara-Guerra H, Waddell TK, Moran MF, Tsao MS, Krizman DB, Burrows J.
Clin Proteomics. 2012 May 3;9(1):5. [Epub ahead of print
22554165
[PubMed - as supplied by publisher] Free Article nohighlight
Related citations
Opposite regulation by PI3K/Akt and MAPK/ERK pathways of tissue factor expression, cell-associated procoagulant activity and invasiveness in MDA-MB-231 cells.
Hu C, Huang L, Gest C, Xi X, Janin A, Soria C, Li H, Lu H.
J Hematol Oncol. 2012 Apr 25;5(1):16. [Epub ahead of print
22534171
[PubMed - as supplied by publisher] Free Article nohighlight
Related citations
NADPH oxidase-produced superoxide mediates EGFR transactivation by c-Src in arsenic trioxide-stimulated human keratinocytes.
Tseng HY, Liu ZM, Huang HS.
Arch Toxicol. 2012 Apr 25. [Epub ahead of print
22532027
[PubMed - as supplied by publisher] nohighlight
Related citations
Cetuximab in non-melanoma skin cancer.
Wollina U.
Expert Opin Biol Ther. 2012 Apr 23. [Epub ahead of print
22519406
[PubMed - as supplied by publisher] nohighlight
Related citations
Muscarinic Type 3 Receptor Induces Cytoprotective Signaling in Salivary Gland Cells Via EGFR Transactivation.
Kajiya M, Ichimonji I, Min C, Zhu T, Jin JO, Yu Q, Almazrooa SA, Cha S, Kawai T.
Mol Pharmacol. 2012 Apr 17. [Epub ahead of print
22511543
[PubMed - as supplied by publisher] Free Article nohighlight
Related citations
Anti-tumor mechanisms of targeting the PDK1 pathway in head and neck cancer.
Bhola NE, Freilino ML, Joyce SC, Sen M, Thomas SM, Sahu A, Cassell A, Chen CS, Grandis JR.
Mol Cancer Ther. 2012 Apr 5. [Epub ahead of print
22491800
[PubMed - as supplied by publisher] nohighlight
Related citations
The endothelin A receptor and epidermal growth factor receptor signaling converge on β-catenin to promote ovarian cancer metastasis.
Cianfrocca R, Tocci P, Spinella F, Di Castro V, Bagnato A, Rosanò L.
Life Sci. 2012 Mar 28. [Epub ahead of print
22480520
[PubMed - as supplied by publisher] nohighlight
Related citations
Management of EGFR-inhibitor associated rash: a retrospective study in 49 patients.
Gerber PA, Meller S, Eames T, Buhren BA, Schrumpf H, Hetzer S, Ehmann LM, Budach W, Bölke E, Matuschek C, Wollenberg A, Homey B.
Eur J Med Res. 2012 Feb 23;17(1):4
22472354
[PubMed - in process] Free PMC Article nohighlight
Related citations
Consistent mutation status within histologically heterogeneous lung cancer lesions.
Mattsson JS, Imgenberg-Kreuz J, Edlund K, Botling J, Micke P.
Histopathology. 2012 Mar 28. doi: 10.1111/j.1365-2559.2012.04245.x. [Epub ahead of print
22458769
[PubMed - as supplied by publisher] nohighlight
Related citations
Molecular and genetic bases of pancreatic cancer.
Vaccaro V, Gelibter A, Bria E, Iapicca P, Cappello P, Di Modugno F, Pino MS, Nuzzo C, Cognetti F, Novelli F, Nisticò P, Milella M.
Curr Drug Targets. 2012 Mar 29. [Epub ahead of print
22458519
[PubMed - as supplied by publisher] nohighlight
Related citations
Erlotinib Associated Exacerbation of Hypothyroidism with Pericardial Tamponade.
Kastoon T, Stump CS, Thomson SP, Yassine H.
Endocr Pract. 2012 Mar 22:1-7. [Epub ahead of print
22440982
[PubMed - as supplied by publisher] Free Article nohighlight
Related citations
Folliculitis Induced by EGFR Inhibitors, Preventive and Curative Efficacy of Tetracyclines in the Management and Incidence Rates According to the Type of EGFR Inhibitor Administered: A Systematic Literature Review.
Bachet JB, Peuvrel L, Bachmeyer C, Reguiai Z, Gourraud PA, Bouché O, Ychou M, Bensadoun RJ, Dreno B, André T.
Oncologist. 2012;17(4):555-68. Epub 2012 Mar 16
22426526
[PubMed - in process] nohighlight
Related citations
Enhancement of the cytotoxic potential of the mixed EGFR and DNA-targeting 'combi-molecule' ZRBA1 against human solid tumour cells by a bis-quinazoline-based drug design approach.
Al-Safadi S, Domarkas J, Han Y, Brahimi F, Jean-Claude BJ.
Anticancer Drugs. 2012 Jun;23(5):483-93
22421369
[PubMed - in process] nohighlight
Related citations
Synergistic Effects of Erlotinib and Everolimus on Bronchial Carcinoids and Large-Cell Neuroendocrine Carcinomas with Activated EGFR/AKT/mTOR Pathway.
Bago-Horvath Z, Sieghart W, Grusch M, Lackner A, Hayden H, Pirker C, Komina O, Węsierska-Gądek J, Haitel A, Filipits M, Berger W, Schmid K.
Neuroendocrinology. 2012 Feb 24. [Epub ahead of print
22378048
[PubMed - as supplied by publisher] Free Article nohighlight
Related citations
A Phase II Study of Lapatinib in Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck.
de Souza JA, Davis DW, Zhang Y, Khattri A, Seiwert TY, Aktolga S, Wong SJ, Kozloff MF, Nattam S, Lingen MW, Kunnavakkam R, Stenson KM, Blair EA, Bozeman J, Dancey JE, Vokes EE, Cohen EE.
Clin Cancer Res. 2012 Apr 15;18(8):2336-2343. Epub 2012 Feb 27
22371453
[PubMed - as supplied by publisher] nohighlight
Related citations